By Chloe Chae
June 4, 2026 · 4 min readPatients with hard-to-treat depression got significantly better after one to four psilocybin sessions, according to a new analysis of real hospital records at University Hospital Zurich in Switzerland.
The sessions use psilocybin, the active compound in so-called magic mushrooms. Under medical supervision, a patient takes a measured dose, then rests for several hours wearing eyeshades and listening to music while trained therapists stay nearby to guide the experience. Most programs add preparation meetings before the dose and follow-up talks afterward, a step clinicians call integration.
The Zurich results matter because they show the drug working outside a carefully controlled study, and they push researchers toward a bigger question: whether the moment of insight a patient experiences during the session, not the drug itself, does the real healing.
Doctors pulled the records from patients with treatment-resistant depression, meaning their depression did not respond to at least two standard medicines.
Standard antidepressants can take several weeks to produce any effect and often stop working over time, which leaves many patients without a reliable long-term option.
After one to four supervised sessions with psilocybin, many of those same patients reported far lighter symptoms.
Real hospital records carry a special kind of value, because patients in regular clinics do not follow the neat rules of a laboratory experiment, so positive results from that setting reassure doctors that the drug actually works in practice.
Brain research adds another layer to the story.
A single psilocybin dose can change the way different parts of the brain communicate with each other, and those changes can last for weeks after the drug leaves the body.
Scientists connect that staying power to neuroplasticity, or the brain's ability to build new connections and pathways between neurons, as one imaging study explained.
Researchers now debate which part of the experience actually does the healing.
Recent findings suggest that the psychological insight a patient reaches during the hallucinatory hours matters more than the drug's direct chemical action on the brain.
Psilocybin appears to soften the stuck patterns of thinking that depression creates, giving patients a window to try on new ways of understanding themselves and their situation.
Trained therapists sit with patients through those hours and help them work through whatever comes up, making that guided conversation a core part of the treatment rather than a side note.
That approach sets psychedelic therapy apart from a daily pill, because a pill only reduces symptoms while the patient keeps taking it, but a single guided session aims to shift how a person thinks in a way that holds on its own.
Regulators have started to respond to the research.
The United States Food and Drug Administration recently began fast-tracking its review of psilocybin and similar therapies.
United States federal law still lists psilocybin under Schedule I, the toughest legal category, covering drugs the government says carry a high risk of misuse and no accepted medical purpose.
That legal status keeps debate open about addiction risk and long-term effects, since long-term safety remains unconfirmed.
Money adds another barrier. Because regulators have not approved psilocybin as a standard medicine, insurance rarely covers it, and supervised sessions in the few places that permit them can cost well over a thousand dollars each. The hours of therapist time every session demands keep the price high and the treatment out of reach for most patients.
Clinical trials continue to add evidence.
A Phase 2 trial at Karolinska Institutet in Sweden, an early-stage human study testing whether the treatment works, found rapid relief from depression symptoms after just one dose.
A separate Phase 2 study confirmed the same fast drop in symptoms from a single dose, backing up the finding across independent research teams.
Scientists say psychedelic therapy could mark a major change in how doctors treat depression, shifting focus from reducing symptoms to helping patients fundamentally rethink their own pain.
Researchers across the field agree on one firm point that these treatments belong only inside a proper medical setting, never outside one.
